Summary & Overview
HCPCS S3840: RET Germline Mutation Analysis for MEN2 Susceptibility
HCPCS Level II code S3840 designates DNA analysis for germline mutations in the RET proto-oncogene to evaluate susceptibility to multiple endocrine neoplasia type 2 (MEN2). As a targeted molecular diagnostic test, this code captures services used to identify hereditary RET variants that have clinical implications for cancer risk, surveillance, and family counseling. The code is important nationally as precision oncology and hereditary cancer genetics expand across clinical settings, affecting coverage decisions, lab billing, and care pathways.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for RET testing, what the code represents for billing and service classification, and typical sites where the testing is performed. The publication also summarizes payer coverage considerations and common billing modifiers used with laboratory services where available. Benchmarks, reimbursement patterns, and recent policy updates relevant to molecular diagnostic billing are presented where data exists.
This summary is intended for revenue cycle leaders, laboratory managers, genetics clinicians, and policy analysts seeking a concise reference on the role and classification of S3840 in the current healthcare billing landscape. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S3840 describes DNA analysis for germline mutations of the RET proto-oncogene to assess susceptibility to multiple endocrine neoplasia type 2 (MEN2). This service is a molecular genetic diagnostic test that targets hereditary variants in the RET gene associated with familial medullary thyroid carcinoma and other MEN2-related tumors.
Service type: Genetic testing / Molecular diagnostic analysis
Typical site of service: Clinical molecular laboratory or specialized genetic testing laboratory, with specimen collection commonly performed in outpatient clinics or hospital phlebotomy units.
Clinical & Coding Specifications
Clinical Context
A patient is referred to a genetics clinic for evaluation of suspected hereditary multiple endocrine neoplasia type 2 (MEN2) after a personal or family history of medullary thyroid carcinoma, pheochromocytoma, or primary hyperparathyroidism. Typical patients include an adult with a newly diagnosed medullary thyroid carcinoma, an individual with an affected first-degree relative, or an asymptomatic relative undergoing predictive testing. The clinical workflow begins with pre-test genetic counseling addressing test purpose, possible results, and implications. A peripheral blood sample or saliva specimen is collected and sent to a molecular diagnostics laboratory where S3840 is performed to analyze the germline RET proto-oncogene for pathogenic variants associated with MEN2A, MEN2B, and familial medullary thyroid carcinoma. Results are returned to the ordering provider and genetic counselor, followed by post-test counseling to discuss positive, negative, or variant of uncertain significance findings and management implications for surveillance, prophylactic surgery, and cascade testing of relatives. Typical site of service is an outpatient genetics clinic or hospital outpatient laboratory collection center; molecular testing is performed in a CLIA-certified molecular laboratory.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the laboratory documents and bills for substantially greater effort or complexity in analysis or reporting beyond usual testing (rare for standard molecular assays). |